Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Revenue | 1.29B | 0.8% |
| Gross Profit | 766M | 2% |
| Cost of Revenue | 525M | 1% |
| Operating expense | 340M | 1.8% |
| Net Income | 365M | 5.9% |
| EBITDA | 426M | 17.7% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 7.57B | 6% |
| Total Liabilities | 2.02B | 7% |
| Total Equity | 5.55B | 5.6% |
| Shares Outstanding | 147M | 0.3% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | 579M | 87.5% |
| Cash from financing | -144M | 2.3% |
EPS
Financial Highlights for Resmed in Q1 '25
Resmed reported a revenue of 1.29B, which is a 0.8% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 766M, marking a 2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 525M, a -1% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 340M, showing a 1.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 365M, showing a 5.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 426M, showing a 17.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Resmed with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
